

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

---

# **Application of a sedation scoring system in dogs following premedication**

---

Thesis is submitted by Deepti Deshpande  
to fulfil the requirements for the degree  
of  
Masters of Veterinary Studies  
in the  
Institute of Veterinary, Animal and Biomedical Sciences  
College of Sciences  
Massey University, Palmerston North, New Zealand  
31 July 2014

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

*To Mom, Dad and Prathmesh,*

*You have been my inspiration and my strength. Thank you for being a part of my life!*

## Acknowledgements

I would like to express my gratitude to my supervisors Dr Mike Giesege and Dr Kate Hill for their endless support and encouragement. They have been the driving force behind this project and without their supervision and guidance this project would not have been possible. I am deeply indebted to Prof Boyd Jones who has been my mentor and a constant source of inspiration providing me with countless learning opportunities during my 2 years at Massey University.

I would like to express my gratitude to Prof Katrina Mealey who has been a co-researcher in this project and was very gracious to help us with the *MDR1* genotyping. A special thanks to Janis Bridges for helping me with the statistics and making it simple for me to understand.

I owe thanks to all the collie parents specially Raewyn Mullen for enrolling her beloved pets in this study. This study would not have been possible without the enthusiasm and the eagerness of all the collie parents. A special thanks to Rachel Thomas who helped me with the sedation scoring and was willing to spend 8 long hours in a consult room observing the dogs.

I would like to extend my thanks to my friends and colleagues at Massey University for helping me at every stage of my thesis and for all the good memories. I am truly blessed to have been born in such a loving and caring family and have parents that taught me to follow my dreams. I can't thank my parents enough for giving me so many opportunities, unconditional love and support and all the exposure I needed in order to grow. I owe thanks to my parents-in-law, who have been just as supportive of my career and passion. Last but by no means the least, I am truly thankful to my ever supportive husband, Prathmesh. I am deeply grateful to him for believing in me, encouraging me at all times and surviving three long years of long distance relationship.

## Abstract

Pharmacogenetics is the study of how variations in the genome influence drug pharmacokinetics (the body's effect on the drug) and pharmacodynamics (the drug's effect on the body). The *MDR1* gene codes for a membrane-bound drug transporter protein, P-glycoprotein (P-gp) that transports drugs across the cell membrane using an energy-dependent mechanism. Anecdotal reports in the literature suggested that dogs with a mutation in the *MDR1* gene (*MDR1-1Δ*) show increased sensitivity to routinely used veterinary sedatives such as acepromazine and butorphanol, resulting in increased duration and depth of sedation. This study has 3 aims. First is to gain experience with a sedation scoring system that can be used to assess the level of sedation. The second aim is to assess the difference in sedation of dogs premedicated with dexmedetomidine and acepromazine. The third aim is to investigate the effect of acepromazine (n=29) and a combination of acepromazine and butorphanol (n=12) on *MDR1* genotyped rough-coated collies.

In the study assessing the sedation of dogs premedicated with dexmedetomidine and acepromazine, 30 dogs scheduled for orchidectomy were divided into two groups; the DEX group (n=15) and the ACE group (n=15). Dogs in the DEX group received dexmedetomidine (125 µg/m<sup>2</sup>) and morphine (0.5 mg/kg) while the dogs in the ACE group received acepromazine (0.04 mg/kg) and morphine (0.5 mg/kg). The dogs were sedation scored at 0, 10, 20 and 30 minute intervals. The dogs in the DEX group had a statistically higher sedation score at 30 minutes than the dogs in the ACE group (*p* value =0.0189). Dogs premedicated with dexmedetomidine had a higher sedation score than dog's premedicated acepromazine at 30 minutes. The heart rate, respiratory rate and mean arterial blood pressure were not different between the DEX and the ACE group at 30 minutes post administration of premedication agent.

The second study investigated the effects of acepromazine and a combination of acepromazine and butorphanol in dogs carrying the *MDR1-1Δ* mutation. Genotyping for the *MDR1-1Δ* mutation was performed in 31 rough-coated collies. Dogs were considered healthy based on clinical history, physical examination, complete blood count, serum chemistry and urinalysis. Twenty-nine of the 31 rough coated collies were deemed healthy and were enrolled in the sedation trial assessing the effects of

acepromazine on the *MDR1-1Δ* mutants. A subset of the 29 rough coated collies was enrolled in the study assessing the effects of combination of acepromazine and butorphanol. The rough coated collies were divided in 3 groups based on their genotype: homozygous mutants, heterozygous carriers and normal group. After administration of acepromazine (0.04 mg/kg, IV) or a combination of acepromazine (0.04 mg/kg) and butorphanol (0.05 mg/kg), sedation scoring was performed at 0, 30 minutes, 60 minutes, 90 minutes, 2 , 2.5 , 3 , 4 and 6 hour intervals by an observer blinded to the results of the *MDR1* genotype. Following administration of acepromazine, homozygous mutant collies (*MDR1 -/-*) (n = 10) reached a greater level of sedation and remained sedated for a longer duration as compared to the heterozygous carriers (*MDR1 +/-*) (n =10) and wild-type collies (*MDR1 +/+*) (n = 9) ( $p= 0.0176$ ). A subset of 12 dogs was sedated with a combination of acepromazine (0.04 mg/kg) and butorphanol (0.05 mg/kg). Heterozygous carriers (*MDR1 -/+*) had significantly higher sedation scores than homozygous mutants (*MDR1 -/-*) and normal groups (*MDR1 +/+*) when sedated with the combination ( $p=0.0423$ ). This unexpected result may have been due to the small number of dogs tested. The author recommends lower dosing of acepromazine and butorphanol in dogs that are homozygous mutants to the *MDR1-1Δ* mutation and recommends the constant monitoring of sedation.

# Table of Contents

<b>Acknowledgements .....</b>	<b>4</b>
<b>Abstract.....</b>	<b>5</b>
<b>Lists of tables.....</b>	<b>10</b>
<b>Lists of Figures.....</b>	<b>12</b>
<b>Abbreviations .....</b>	<b>14</b>
<b>1. Introduction.....</b>	<b>16</b>
1.1 Balanced Anaesthesia .....	16
1.2 Premedication .....	18
1.2.1 Anticholinergics .....	18
A. Atropine .....	19
B. Glycopyrrolate .....	19
1.2.2 Pre-emptive analgesia.....	21
Neurobiology of pain.....	21
1.2.3 Sedatives.....	23
A. Phenothiazines .....	23
Acepromazine.....	24
B. Alpha-2-adrenergic agonist.....	25
Dexmedetomidine.....	27
C. Benzodiazepines .....	27
D. Opioids.....	28
1.3 Sedation: clinical implications.....	31
1.4 Sedation Scoring Scales.....	32
1.5 Pharmacogenetics .....	36
Basic Genetics Concepts .....	37
CYP2D15 in Beagles.....	38
CYP2D11 in greyhounds.....	39
Thiopurine Methyltransferase (TPMT) in Giant Schnauzers and Alaskan Malamutes .....	39
Malignant Hyperthermia.....	40
MDR1 Gene.....	40
Overview of P-glycoprotein .....	41
ABC transporters .....	42
Structure of P-glycoprotein .....	42

Function of P-glycoprotein.....	44
Role of P-glycoprotein in intestinal drug absorption.....	47
Role of P-glycoprotein in drug disposition.....	49
Role of P-glycoprotein in excretion.....	51
<i>MDR1-1Δ</i> Mutation in Dogs.....	54
Breed Distribution of <i>MDR1-1Δ</i> mutation .....	56
Drug Toxicities Associated with <i>MDR1-1Δ</i> Mutation .....	57
<i>MDR1-1Δ</i> : Sedation and Anaesthesia.....	59
Aims of this study.....	60
<b>2. Material and Methods: .....</b>	<b>62</b>
2.1 Comparison of sedation in dogs following administration of dexmedetomidine plus morphine to acepromazine plus morphine .....	62
2.1.1 Animals .....	62
2.1.2 Pre-surgical work up .....	62
2.1.3 Sedation Scoring.....	62
2.1.4 Anaesthesia and Surgery protocol.....	63
2.1.5 Recovery.....	63
2.1.6 Sedation System .....	63
A. Vocalization .....	64
B. Appearance .....	64
C. Interactive Behaviour.....	64
D. Response to sound.....	65
E. Restraint during instrumentation.....	65
F. Gait.....	65
G. Posture.....	65
2.2 Pharmacogenetic effects of <i>MDR1-1Δ</i> mutation on sedation of rough coated collies with acepromazine and a combination of acepromazine and butorphanol. ....	67
2.2.1 Animals .....	67
2.2.2 Buccal Swabs .....	67
2.2.3 Genotyping .....	68
2.2.4 Pre-sedation work up.....	68
A. History.....	69
B. Blood Testing.....	69
C. Urine analysis.....	69

D. Physical Examination.....	70
2.2.5 Sedation Scoring.....	70
A. Sedation scoring following administration of acepromazine alone.....	70
B. Sedation scoring following administration of a combination of acepromazine and butorphanol	71
2.3 Statistical Analysis:.....	72
A. Comparison of sedation in dogs following administration of dexmedetomidine plus morphine to acepromazine plus morphine .....	72
B. Pharmacogenetic effects of MDR1-1Δ on the level of sedation following administration of acepromazine alone.....	73
C. Pharmacogenetic effects of MDR1-1Δ on the level of sedation following administration of combination of acepromazine and butorphanol. ....	73
<b>3. Results: Comparison of sedation in dogs following administration of dexmedetomidine plus morphine to acepromazine plus morphine .....</b>	<b>75</b>
<b>4.Results:.....</b>	<b>82</b>
4.1 Pharmacogenetic effects of <i>MDR1-1Δ</i> mutation on sedation of rough coated collies with acepromazine .....	82
4.2 Pharmacogenetic effects of <i>MDR1-1Δ</i> mutation on sedation of rough coated collies with combination of acepromazine and butorphanol. ....	90
<b>5. Discussion: .....</b>	<b>98</b>
5.1 Comparison of sedation in dogs following administration of dexmedetomidine plus morphine to acepromazine plus morphine .....	98
5.2 Pharmacogenetic effects of <i>MDR1-1Δ</i> mutation on sedation of rough coated collies with acepromazine . ....	101
5.3 Pharmacogenetic effects of <i>MDR1-1Δ</i> mutation on sedation of rough coated collies with a combination of acepromazine and butorphanol. ....	106
5.4 Conclusion .....	108
<b>6. References.....</b>	<b>110</b>

## Lists of tables

Table of Contents.....	7
Table 1.1: Opioid Receptor Activity (Adams, 2001), (Pleuvry, 2005) .....	30
Table 1.2: Sedation scoring system (Hofmeister, Chandler, & Read, 2010). .....	35
Figure 1.1: Topological map and domain organisation of P-gp, predicted from its primary sequence (Higgins et al., 1997).....	44
Figure 1.2: P-glycoprotein expression and function in various tissues (Fromm, 2004).....	46
Table 1.3: Selected P-gp substrates (Martinez et al., 2008). .....	53
Figure 1.3: Partial (bases 275±708) sequence comparison of wild-type (top) and mutant (bottom) <i>MDR1</i> cDNAs. ....	55
Figure 1.4: Diagrammatic representation of the transmembrane structure of P-glycoprotein (P-gp) (Mealey et al., 2001).....	56
Table 2.1: Sedation Scoring System, modified from (Hofmeister et al., 2010) .....	66
Table 3.1: Mean + SD Age (years) and Bodyweight (Kg) of dogs in DEX and ACE groups. ....	76
Table 3.2: Breeds of dogs enrolled in DEX groups. ....	76
Table 3.3: Breeds of dogs enrolled in ACE groups. ....	77
Figure 3.1: Comparison of sedation scores between dogs premedicated with dexmedetomidine (DEX) and acepromazine (ACE). ....	78
Figure 3.2: Comparison of heart rates (HR) between dogs in DEX and ACE group following induction with propofol. ....	79
Figure 3.3: Comparison of systolic arterial blood pressure (SAP) between dogs in DEX and ACE following induction with propofol. ....	80
Table 4.1: Name, age, sex and genotype data of 31 rough coated collies in the study.....	83
Table 4.2: Number of dogs, sex, age and weight data from 29 rough coated collies in the trial assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following the IV administration of acepromazine alone. ....	84
Figure 4.1: Mean sedation scores during acclimation period. ....	85
Figure 4.2: Individual sedation scores of 29 rough coated collies. ....	86
Figure 4.3: Comparison of the median recalculated (R) sedation scores and genotypes in the trial assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	87
Figure 4.4: Comparison of the median heart rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	88
Figure 4.5: Comparison of the median respiratory rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	89
Figure 4.6: Comparison of the median mean arterial blood pressure and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	90
Table 4.3: Number of dogs, sex, age and weight data from 12 rough coated collies in the trial assessing the effects of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine and butorphanol combination. ....	91
Figure 4.7: Mean sedation score during acclimation period.....	92

Figure 4.8: Comparison the median recalculated (R) sedation scores and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of combination of acepromazine and butorphanol. ....	93
Figure 4.9: Comparison of the median heart rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	94
Figure 4.10: Comparison of the median respiratory rates and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	95
Figure 4.11: Comparison of the median mean arterial blood pressure and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	96
Table 5.1: Table shows the allelic distribution of <i>MDR1-Δ</i> mutation published in other studies and in the current study.....	101

## Lists of Figures

Table of Contents.....	7
Table 1.1: Opioid Receptor Activity (Adams, 2001), (Pleuvry, 2005) .....	30
Table 1.2: Sedation scoring system (Hofmeister, Chandler, & Read, 2010). .....	35
Figure 1.1: Topological map and domain organisation of P-gp, predicted from its primary sequence (Higgins et al., 1997).....	44
Figure 1.2: P-glycoprotein expression and function in various tissues (Fromm, 2004).....	46
Table 1.3: Selected P-gp substrates (Martinez et al., 2008). .....	53
Figure 1.3: Partial (bases 275±708) sequence comparison of wild-type (top) and mutant (bottom) <i>MDR1</i> cDNAs. ....	55
Figure 1.4: Diagrammatic representation of the transmembrane structure of P-glycoprotein (P-gp) (Mealey et al., 2001).....	56
Table 2.1: Sedation Scoring System, modified from (Hofmeister et al., 2010) .....	66
Table 3.1: Mean + SD Age (years) and Bodyweight (Kg) of dogs in DEX and ACE groups. ....	76
Table 3.2: Breeds of dogs enrolled in DEX groups. ....	76
Table 3.3: Breeds of dogs enrolled in ACE groups. ....	77
Figure 3.1: Comparison of sedation scores between dogs premedicated with dexmedetomidine (DEX) and acepromazine (ACE). ....	78
Figure 3.2: Comparison of heart rates (HR) between dogs in DEX and ACE group following induction with propofol. ....	79
Figure 3.3: Comparison of systolic arterial blood pressure (SAP) between dogs in DEX and ACE following induction with propofol. ....	80
Table 4.1: Name, age, sex and genotype data of 31 rough coated collies in the study. ....	83
Table 4.2: Number of dogs, sex, age and weight data from 29 rough coated collies in the trial assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following the IV administration of acepromazine alone. ....	84
Figure 4.1: Mean sedation scores during acclimation period. ....	85
Figure 4.2: Individual sedation scores of 29 rough coated collies. ....	86
Figure 4.3: Comparison of the median recalculated (R) sedation scores and genotypes in the trial assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	87
Figure 4.4: Comparison of the median heart rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	88
Figure 4.5: Comparison of the median respiratory rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	89
Figure 4.6: Comparison of the median mean arterial blood pressure and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine alone. ....	90
Table 4.3: Number of dogs, sex, age and weight data from 12 rough coated collies in the trial assessing the effects of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of acepromazine and butorphanol combination. ....	91
Figure 4.7: Mean sedation score during acclimation period. ....	92
Figure 4.8: Comparison the median recalculated (R) sedation scores and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of combination of acepromazine and butorphanol. ....	93

Figure 4.9: Comparison of the median heart rate and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	94
Figure 4.10: Comparison of the median respiratory rates and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	95
Figure 4.11: Comparison of the median mean arterial blood pressure and genotypes in the study assessing the effect of <i>MDR1-1Δ</i> mutation on the level of sedation following IV administration of a combination of acepromazine and butorphanol. ....	96
Table 5.1: Table shows the allelic distribution of <i>MDR1-Δ</i> mutation published in other studies and in the current study. ....	101

## Abbreviations

ABC	ATP Binding Cassette Transporter Proteins
ACE	Acepromazine Group
ATP	Adenosine Triphosphate
AUC	Area Under Curve
AV	Atrioventricular
cAMP	Cyclic Adenosine Monophosphate
CBC	Complete Blood Count
CHO	Chinese Hamster Ovary
CNS	Central Nervous System
CSF	Cerebrospinal Fluid
CYP	Cytochrome P450 enzymes
D (1 & 2)	Dopamine Receptors
DD	Deepti Deshpande
DEX	Dexmedetomidine Group
DNA	Deoxyribonucleic acid
GABA	Gamma Amino Butyric Acid
GABA <sub>A</sub>	Gamma Amino Butyric Acid A Receptors
GABA <sub>B</sub>	Gamma Amino Butyric Acid B Receptors
GFR	Glomerular Filtration Rate
GI	Gastrointestinal
HR	Heart Rate
IFN-gamma	Interferon gamma
IM	Intramuscular
IV	Intravenous
M (1-5)	Muscarinic Receptors
MAP	Mean Arterial Pressure
<i>MDR1</i>	Multidrug Resistant-1 gene
<i>MDR1-1Δ</i>	Multidrug Resistant-1-1Δ mutation
MDR1a (-/-)	Multidrug Resistant -1a Knockout
MDR1a (+/+)	Multidrug Resistant -1a Wildtype
MUAEC	Massey University Animal Ethics Committee
MUT/MUT	MDR1-1Δ homozygous mutants
MUT/N	MDR1-1Δ heterozygous carriers
MUVTH	Massey University Veterinary Teaching Hospital
N/N	MDR1-1Δ normal
NBD	Nucleotide Binding Domain
NRS	Normal Saline
NZVP	New Zealand Veterinary Pathology
PCR	Polymerase Chain Reaction
P-gp	P-glycoprotein
R	Recalculated Sedation Score
RAI	Relative Adrenal Insufficiency
RBC	Red Blood Cells
RNA	Ribonucleic acid
RYR1	Ryanodine Receptor-1
SA	Sinoatrial
SAP	Systolic Arterial Pressure
SD	Standard Deviation
SDS	Simple Descriptive Systems
TMD	Transmembrane Domain
USA	United States of America
USDA	United States Department of Agriculture
VAS	Visual Analogue Score
VCPL	Veterinary Clinical Pharmacology Laboratory
WA	Washington State